Capricor Therapeutics Shares Surge 98% as FDA Agrees to Review Deramiocel Application Amendment

RegulatoryDeramiocelPositive

AI Analysis

Summary

Capricor Therapeutics shares surged 98% after the FDA agreed to review an amendment to the Deramiocel application. The company received regulatory acknowledgment to proceed with the review process.

Outcome Details

FDA agreed to review application amendment

Importance:6/10

Sentiment:

0.75

FDAregulatoryDeramiocelapplication amendment

Related Companies

$CAPR

Read the original article

Published by yahoo_finance on August 14, 2026 12:07 PM

Read Original